IL149138A0 - Pharmaceutical compositions containing metformin - Google Patents

Pharmaceutical compositions containing metformin

Info

Publication number
IL149138A0
IL149138A0 IL14913800A IL14913800A IL149138A0 IL 149138 A0 IL149138 A0 IL 149138A0 IL 14913800 A IL14913800 A IL 14913800A IL 14913800 A IL14913800 A IL 14913800A IL 149138 A0 IL149138 A0 IL 149138A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
containing metformin
metformin
pharmaceutical
Prior art date
Application number
IL14913800A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL149138(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL149138A0 publication Critical patent/IL149138A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL14913800A 1999-11-03 2000-10-13 Pharmaceutical compositions containing metformin IL149138A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent

Publications (1)

Publication Number Publication Date
IL149138A0 true IL149138A0 (en) 2002-11-10

Family

ID=23716278

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14913800A IL149138A0 (en) 1999-11-03 2000-10-13 Pharmaceutical compositions containing metformin
IL149138A IL149138A (en) 1999-11-03 2002-04-15 Pharmaceutical preparations containing metformin
IL149139A IL149139A (en) 1999-11-03 2002-04-15 Use of metformin and gliboride for the preparation of pharmaceuticals

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL149138A IL149138A (en) 1999-11-03 2002-04-15 Pharmaceutical preparations containing metformin
IL149139A IL149139A (en) 1999-11-03 2002-04-15 Use of metformin and gliboride for the preparation of pharmaceuticals

Country Status (34)

Country Link
US (2) US6586438B2 (cs)
EP (1) EP1253944A2 (cs)
JP (2) JP2003529551A (cs)
KR (2) KR100769786B1 (cs)
CN (3) CN101273981B (cs)
AR (1) AR026355A1 (cs)
AU (1) AU781781B2 (cs)
BG (2) BG106732A (cs)
BR (1) BR0015295A (cs)
CA (1) CA2389931A1 (cs)
CZ (2) CZ20021547A3 (cs)
DE (1) DE60038455T2 (cs)
EE (1) EE05210B1 (cs)
ES (1) ES2302702T3 (cs)
GE (2) GEP20053538B (cs)
HK (1) HK1045655A1 (cs)
HU (1) HUP0300642A3 (cs)
IL (3) IL149138A0 (cs)
LT (1) LT5025B (cs)
LV (1) LV12907B (cs)
MX (1) MXPA02004290A (cs)
MY (2) MY136636A (cs)
NO (1) NO20022086L (cs)
NZ (1) NZ552074A (cs)
PL (1) PL366112A1 (cs)
RO (1) RO123109B1 (cs)
RU (1) RU2276604C2 (cs)
SK (1) SK4992002A3 (cs)
TN (2) TNSN00207A1 (cs)
TW (1) TWI241185B (cs)
UA (2) UA76706C2 (cs)
UY (1) UY26425A1 (cs)
WO (1) WO2001032158A2 (cs)
ZA (2) ZA200203368B (cs)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
KR100873585B1 (ko) * 2000-03-17 2008-12-11 아지노모토 가부시키가이샤 당뇨병성 합병증용 약제
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
MXPA04002702A (es) * 2001-09-28 2004-07-05 Sun Pharmaceutical Ind Ltd Forma de dosificacion para el tratamiento de diabetes mellitus.
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1482919T3 (da) 2002-01-25 2007-07-30 Silanes Sa De Cv Lab Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
EP2028192A1 (en) * 2002-07-04 2009-02-25 Zealand Pharma A/S GLP-1 and methods for treating diabetes
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
JP2007535557A (ja) * 2004-04-29 2007-12-06 アンドルクス ラブス，エルエルシー 制御放出メトフォルミン組成物
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
RU2308265C2 (ru) * 2005-07-25 2007-10-20 Илья Николаевич Медведев Способ выбора лечения тромбоцитопатии при метаболическом синдроме
JP2009518429A (ja) * 2005-12-09 2009-05-07 メタプロテオミクス，エルエルシー 代謝症候群および糖尿病の治療のための抗炎症植物産物
MY152172A (en) * 2005-12-28 2014-08-15 Takeda Pharmaceutical Therapeutic agent for diabetes
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP2051732A4 (en) * 2006-07-26 2009-10-21 Diamedica Inc DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
PL3222277T3 (pl) 2009-03-31 2020-08-24 Ligand Pharmaceuticals Inc. Bifenylosulfonamid będący antagonistą receptora endoteliny i angiotensyny ii do leczenia stwardnienia kłębuszków nerkowych i nefropatii wywołanej iga
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA2759284C (en) 2009-04-29 2016-06-21 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
EA023925B1 (ru) 2010-04-27 2016-07-29 Зилэнд Фарма А/С Пептидные конъюгаты агонистов рецептора glp-1 и их применение
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
DK2568988T3 (en) 2010-05-11 2016-08-22 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US20120177730A1 (en) 2011-01-07 2012-07-12 Elcelyx Therapeutics, Inc. Chemosensory Receptor Ligand-Based Therapies
WO2013064669A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
WO2013181755A1 (en) 2012-06-04 2013-12-12 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
EP2875043B1 (en) 2012-07-23 2016-12-21 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2014336098B2 (en) 2013-10-17 2018-05-10 Boehringer Ingelheim International Gmbh Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015067716A1 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN113677355A (zh) * 2018-09-24 2021-11-19 潘德勒姆治疗公司 微生物组合物及使用方法
SMT202400320T1 (it) 2018-09-24 2024-09-16 Amarin Pharmaceuticals Ie Ltd Metodi di riduzione del rischio di eventi cardiovascolari in un soggetto
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
ES2159184T3 (es) 1997-06-13 2001-09-16 Novo Nordisk As Nueva posologia para la dmni.
EA003144B1 (ru) 1997-06-18 2003-02-27 Смитклайн Бичам Плс Способ лечения диабета тиазолидиндионом и метформином
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
KR20010024533A (ko) 1997-10-17 2001-03-26 오흘러 로스 제이. 퀴놀린 유도체의 치료적 용도
JP4278863B2 (ja) 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
SI0974356T1 (en) 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
CZ2001965A3 (cs) 1998-09-17 2002-02-13 Bristol-Myers Squibb Company Lék pro oąetřování atherosklerózy nebo diabetes typu II, farmaceutická kombinace a její pouľití
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
CN100386114C (zh) 2008-05-07
CN101273981A (zh) 2008-10-01
NZ552074A (en) 2008-06-30
CZ304090B6 (cs) 2013-10-16
AU8022900A (en) 2001-05-14
ZA200203367B (en) 2003-09-10
NO20022086D0 (no) 2002-05-02
BG65850B1 (bg) 2010-03-31
JP2003529551A (ja) 2003-10-07
US20020183345A1 (en) 2002-12-05
MY136636A (en) 2008-11-28
BG106732A (bg) 2003-02-28
MXPA02004290A (es) 2003-02-12
LT5025B (lt) 2003-06-25
WO2001032158A2 (en) 2001-05-10
EE05210B1 (et) 2009-10-15
DE60038455D1 (de) 2008-05-08
KR20020050253A (ko) 2002-06-26
US20020177602A1 (en) 2002-11-28
CZ20021547A3 (cs) 2003-01-15
EE200200241A (et) 2003-12-15
CN1414862A (zh) 2003-04-30
JP2013028631A (ja) 2013-02-07
CA2389931A1 (en) 2001-05-10
KR100769786B1 (ko) 2007-10-24
UA75583C2 (uk) 2006-05-15
BR0015295A (pt) 2003-06-24
RO123109B1 (ro) 2010-11-30
WO2001032158A3 (en) 2002-08-29
DE60038455T2 (de) 2009-04-23
LV12907B (en) 2003-08-20
NO20022086L (no) 2002-06-24
HUP0300642A3 (en) 2006-05-29
GEP20053538B (en) 2005-06-10
US6586438B2 (en) 2003-07-01
HK1045655A1 (zh) 2002-12-06
US7598262B2 (en) 2009-10-06
GEP20053539B (en) 2005-06-10
ZA200203368B (en) 2003-09-02
MY125118A (en) 2006-07-31
TNSN00206A1 (en) 2005-11-10
UY26425A1 (es) 2001-07-31
PL366112A1 (en) 2005-01-24
LT2002062A (en) 2003-03-25
AU781781B2 (en) 2005-06-16
KR20020057994A (ko) 2002-07-12
UA76706C2 (uk) 2006-09-15
RU2002113764A (ru) 2004-03-20
IL149139A (en) 2011-11-30
TNSN00207A1 (en) 2005-11-10
RU2276604C2 (ru) 2006-05-20
ES2302702T3 (es) 2008-08-01
CN102283853A (zh) 2011-12-21
IL149138A (en) 2007-12-03
AR026355A1 (es) 2003-02-05
CN101273981B (zh) 2011-01-26
TWI241185B (en) 2005-10-11
SK4992002A3 (en) 2003-04-01
HUP0300642A2 (hu) 2003-07-28
EP1253944A2 (en) 2002-11-06
BG106733A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
IL149138A0 (en) Pharmaceutical compositions containing metformin
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
PL351387A1 (en) Pharmaceutical composition
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
IL187605A0 (en) Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl)
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
IL149139A0 (en) Pharmaceutical compositions containing metformin and glyburide
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
GB9923436D0 (en) Pharmaceutical compositions
IL146434A0 (en) Pharmaceutical compositions containing ecteinascidin 743
IL161430A0 (en) Pharmaceutical compositions containing ecteinascidin 743
EP1166786A4 (en) MEDICAL COMPOSITIONS
IL137505A (en) Pharmaceutical compositions containing tramadol
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
GB9809213D0 (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
IL148691A0 (en) Pharmaceutical compositions containing ciclesonide
HUP0003836A3 (en) Pharmaceutical compositions containing lasofoxifene
GB9911017D0 (en) Pharmaceutical compositions
IL148725A0 (en) Aqueous pharmaceutical compositions containing circlesonide

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed